Metronidazole microbiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
{{Metronidazole }}
{{CMG}}; {{AE}} {{chetan}}
==Microbiology==
==Microbiology==


Line 11: Line 15:
Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.


Gram-positive anaerobes:
====Gram-positive anaerobes====
*Clostridium species
*[[Clostridium]] species
*Eubacterium species
*[[Eubacterium]] species
*Peptococcus species
*[[Peptococcus]] species
*Peptostreptococcus species
*Peptostreptococcus species


Gram-negative anaerobes:
====Gram-negative anaerobes====
*Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus)
*Bacteroides fragilis group ([[B. fragilis]], B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus)
*Fusobacterium species
*Fusobacterium species


Protozoal parasites:
'''Protozoal parasites:'''
*Entamoeba histolytica
*[[Entamoeba histolytica]]
*Trichomonas vaginalis
*[[Trichomonas vaginalis]]


The following in vitro data are available, but their clinical significance is unknown:
The following in vitro data are available, but their clinical significance is unknown:
Line 29: Line 33:
Metronidazole exhibits in vitro minimum inhibitory concentrations (MICs) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
Metronidazole exhibits in vitro minimum inhibitory concentrations (MICs) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.


Gram-negative anaerobes:
====Gram-negative anaerobes====
*Bacteroides fragilis group (B. caccae, B. uniformis)
*Bacteroides fragilis group (B. caccae, B. uniformis)
*Prevotella species (P. bivia, P. buccae, P. disiens)
*Prevotella species (P. bivia, P. buccae, P. disiens)
Line 42: Line 46:


{|
{|
|-
|-
| [[File: Metro MB1.jpg|800px|thumb]]
| [[File: Metro MB1.jpg|800px|thumb]]
Line 54: Line 57:
===Quality Control===
===Quality Control===


Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2 Standard metronidazole powder should provide a value within the MIC ranges noted in the following table:
Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2 Standard metronidazole powder should provide a value within the MIC ranges noted in the following table:<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = FLAGYL (METRONIDAZOLE) CAPSULE [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2883ca1-5a9a-4259-9d80-46ab67274384 | publisher =  | date =  | accessdate =  }}</ref>
 
 
{|
{|
|-
|-
| [[File: Metro MB2.jpg|800px|thumb]]
| [[File: Metro MB2.jpg|800px|thumb]]
|-
|-
|}
|}
==References==
{{Reflist}}
{{FDA}}
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Latest revision as of 00:35, 9 January 2014

Metronidazole
Flagyl® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Microbiology

Mechanism of Action

Metronidazole exerts antibacterial effects in an anaerobic environment by the following possible mechanism: Once metronidazole enters the organism, the drug is reduced by intracellular electron transport proteins. Because of this alteration to the metronidazole molecule, a concentration gradient is maintained which promotes the drug's intracellular transport. Presumably, free radicals are formed which, in turn, react with cellular components resulting in death of the bacteria.

Metronidazole is active against most obligate anaerobes, but does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes.

Activity In Vitro and In Vivo

Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Gram-positive anaerobes

Gram-negative anaerobes

  • Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus)
  • Fusobacterium species

Protozoal parasites:

The following in vitro data are available, but their clinical significance is unknown:

Metronidazole exhibits in vitro minimum inhibitory concentrations (MICs) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.

Gram-negative anaerobes

  • Bacteroides fragilis group (B. caccae, B. uniformis)
  • Prevotella species (P. bivia, P. buccae, P. disiens)

Susceptibility Test Methods

When available, the clinical microbiology laboratory should provide results of in vitro susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.

Anaerobic techniques

Quantitative methods are used to determine antimicrobial inhibitory concentrations (MICs) provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. For anaerobic bacteria, the susceptibility to metronidazole can be determined by the reference broth or agar dilution method1,2. The MIC values obtained should be interpreted according to the following criteria:

For protozoal parasites: Standardized tests do not exist for use in clinical microbiology laboratories.

A report of "Susceptible" indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug product can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2 Standard metronidazole powder should provide a value within the MIC ranges noted in the following table:[1]



References

  1. "FLAGYL (METRONIDAZOLE) CAPSULE [G.D. SEARLE LLC DIVISION OF PFIZER INC]".

Adapted from the FDA Package Insert.